Category PRECISION MEDICINE

PIER MARIA FORNASARI
2019-10-30

European Commission Approves Bavencio-Inlyta for First-line Treatment of Advanced Kidney Cancer

The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted prognosis and PD-L1 status. The EC’s decision followed a positive recommendation issued in September by the Committee for Medicinal

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2019-10-30

BRAF/MEK inhibitor therapy induces response in metastatic melanoma with rare BRAF mutations

Combination therapy with BRAF and MEK inhibitors conferred significant PFS benefit compared with BRAF inhibitor monotherapy among patients with metastatic melanoma with rare BRAF mutations or translocations, according to results of an international, retrospective study published in Journal of Clinical Oncology. “Patients with rare BRAF mutations may respond to targeted therapy, however, efficacy seems to be lower compared with patients

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-10-29

Immunotherapy Advances: 2019

The year 2019 has offered up many advances in immunotherapy. These advances shed light on such important aspects as biomarkers, better targeted therapies, chemotherapy outcomes, and resistance. Summarized herein are several high-profile conference presentations that highlight key advances in the field. The year has not quite come to an end yet, but as predicted by

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2019-10-28

CAN SOLAR TECHNOLOGY KILL CANCER CELLS?

The results, published in the current issue of Scientific Reports, showcase dramatic improvements in light-activated fluorescent dyes for disease diagnosis, image-guided surgery and site-specific tumor treatment. Scientific breakthroughs don’t always happen in labs. For Sophia and Richard Lunt, Michigan State University researchers, many of their breakthroughs happen during neighborhood walks. The married couple’s step-by-step approach

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-10-25

Researchers identify possible approach to block medulloblastoma growth

UNC Lineberger’s Timothy Gerson, MD, PhD, and colleagues have identified a potential approach to stop the growth of the most common type of brain tumor in children. Their research was published in the journal Development. UNC Lineberger’s Timothy Gerson, MD, PhD and colleagues reported in the journal Development that by blocking a signal called GSK-3, they could control tumor

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-10-23

Bloomberg Philanthropies, Johns Hopkins University School of Medicine, and The New York Stem Cell Foundation Research Institute Announce an Unprecedented Effort to Advance Precision Medicine

Unmatched Scope of Resources Will Identify Distinctive Disease Mechanisms in Small Patient Subgroups, Supporting Development of Custom Therapeutic Approaches Source NYSCF Bloomberg Philanthropies, Johns Hopkins University School of Medicine (JHUSOM), and The New York Stem Cell Foundation (NYSCF) Research Institute today announced an initiative to fundamentally advance and expand the science of precision medicine, in

Read More

No Comments InPRECISION MEDICINE